ALOX5 and Familial prostate cancer: In contrast, the median methylation difference of the three investigated targets was notably higher (33–38% across the three targets) in UCa-patients with median methylation differences for ALOX5, TRPS1 and Chromosome 16 of 25%, 19% and 16% when compared to prostate cancer, and very similar or identical (26%, 21% and 16%) for the three targets when compared to kidney cancer, respectively (Fig. 2A–C).